This report demonstrates tolerability and efficacy of Sotatercept in portopulmonary hypertension, identifies candidate biomarkers of treatment response, but also suggests caution may be warranted. Findings from this work support further investigation of Sotatercept in the treatment of portopulmonary hypertension.
Jose et al. (Tue,) studied this question.